VENLAFAXINE AND CYP2D6 IN CLINICAL PRACTICE: AN OBSERVATIONAL STUDY
Assoc. Prof. Patrizia Zeppegno
Italy 
1 slide(s) – English – 2011-03-15
VENLAFXINE AND CYP2D6 IN CLINICAL PRACTICE: AN OBSERVATIONAL STUDY
Zeppegno P*, Rolla R**, Dalò V*, Ressico F*, Parafioriti A*, Prosperini P*, Vidali M**, Bellomo G**, Torre E*
*Institute of Psychiatry, Department of Clinical and Experimental Medicine, University of East Piedmont \"Amedeo Avogadro\", Novara, Italy.
**Molecular Diagnostics Laboratory, Department of Medical Sciences, University of East Piedmont \"Amedeo Avogadro\", Clinical Chemistry Unit, Novara, Italy.
Introduction
Venlafaxine is a serotonin-norepinephrine inhibitor, mainly metabolized by CYP2D6 to its active metabolite ODV. Depending on CYP2D6 activity, patients may be identified as Poor, Intermediate, Extensive or Ultrarapid Metabolizers. There is some evidence that a PM phenotype is associated with poor tolerance more often than an EM; while a UM patient would only respond to a greater dose of Venlafaxine1.
Objectives
To evaluate the impact of CYP2D6 phenotype on the efficacy of Venlafaxine XR in depressed patients.
Methods
This observational study evaluated 34 Caucasian adult patients (F=, M= ), satisfying DSM-IV criteria for Major Depressive Disorder, Dysthymia, Adjustment Disorder receiving treatment with Venlafaxine 75-300mg/die.
CYP2D6 alleles were evaluated with INFINITI CYP2D6 assay which utilizes AutoGenomics proprietari film-based microarray technology.
Results
Most patients were identified as EMs, 4 as PMs, while only one was identified as UM.
The only statistically significant difference between Extensive and Poor Metabolizers was, in contrast with current literature, the need of a greater mean dose of Venlafaxine in the second group (225 mg/die vs 159.38 mg/die, t student: p=0.01).
Likewise, in contrast with literature, the UM patient (whom was not considered in our statistical analysis) was responsive to average doses of Venlafaxine.
On the contrary, we found no statistically significant differences as far as efficacy, adverse events or duration of treatment are concerned.
Conclusions
In our sample, the CYP2D6 metabolizer status does not seem to affect treatment response nor adverse events related to Venlafaxine
1. Kirchheiner J. Et al, clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes, biochimica et Biophysica Acta 1770 (2007) 489-494
|
|
